Success factors in drug discovery and development
DOI:
https://doi.org/10.18063/APM.2016.02.002Keywords:
pharmaceutical industry, productivity factorsAbstract
The article aimed to give a personal perspective on drug discovery and development. The author has worked both in Big Pharma as a scientist and manager and more recently also in start-up biotech companies. Drug companies have played a major important role in improving population health and will continue to do so. The hurdles and costs for drug development have continuously risen without a parallel enhancement of productivity. There is no single explanation for this and the article outlines success factors and hurdles for effective drug development. Aspects of the external and internal environments that influence Big Pharma productivity is outlined and discussed.References
Paul M S, Mytelka D S, Dunwiddie C T, et al. 2010, How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, vol.9: 203–214. http://dx.doi.org/10.1038/nrd3078
Herper M, 2011, A decade in drug industry layoffs, Forbes, viewed June 10, 2016, <http://www.forbes.com/sites/matthewherper/2011/04/13/a-decade-in-drug-industry-layoffs/#4e9be1c25614>
Kontis V, Mathers C D, Rehm J, et al. 2014, Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modeling study. The Lancet, vol.384(9941): 427–437. http://dx.doi.org/10.1016/S0140-6736(14)60616-4
Nilsson T, 2010, When Sweden Sold the Nobel Prize Industry: The Story of Astra, Pharmacia and Kabi. Stockholm: SNS Förlag, Swedish.
Kola I and Landis J, 2004, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, vol.3: 711–715. http://dx.doi.org/10.1038/nrd1470
Schuster D, Lagger C and Langer T, 2005, Why drugs fail — a study on side effects in new chemical entities. Current Pharmaceutical Design, vol.11(27): 3545–3559. http://dx.doi.org/10.2174/138161205774414510
Holland R L, 2016, What makes a good biomarker? Advances in Precision Medicine, vol.1(1): 4–11. http://dx.doi.org/10.18063/APM.2016.01.007